John Mao

Featured in: Favicon

Articles

Efficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2/3 trial

Apr 10, 2024 | thelancet.com | George Zhang |John Mao |Xia Chen |Lisa Mu

SummaryGST-HG171 is a potent, broad-spectrum, orally bioavailable small-molecule 3C like protease inhibitor that has demonstrated greater potency and efficacy compared to Nirmatrelvir in pre-clinical studies. We aimed to evaluate the efficacy and safety of orally administered GST-HG171 plus Ritonavir in patients with coronavirus disease 2019 (COVID-19) infected with emerging XBB and non-XBB variants.
Democratizing AI for the Enterprise with NVIDIA DGX SuperPOD and VAST

May 17, 2023 | vastdata.com | John Mao

Today we’re pleased to announce that VAST Data is officially certified for NVIDIA DGX SuperPOD, the industry’s leading accelerated infrastructure platform built for the world’s most challenging AI workloads. NVIDIA and VAST have long shared a common vision for making AI more accessible for all organizations, making today a memorable milestone in the long-standing partnership between our two companies.

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.